There are currently 1084 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
NCT05199285
Recruiting
This phase II trial tests whether nivolumab and ipilimumab works to shrink tumors in patients with liver cancer that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Nivolumab and ipilim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Register for Updates
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
NCT04042831
Recruiting
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Register for Updates
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
NCT03420014
Recruiting
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
Gender:
ALL
Ages:
Between 16 years and 100 years
Trial Updated:
10/06/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leiomyosarcoma
Register for Updates
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
NCT05875948
Recruiting
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/29/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hepatorenal Syndrome, Acute Kidney Injury
Register for Updates
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04786574
Recruiting
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 28 days and 12 weeks
Trial Updated:
09/14/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Register for Updates
Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
NCT05680233
Recruiting
This study is a Phase 1, first-in-human single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of OA-235i in subjects with nonalcoholic steatohepatitis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/05/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Register for Updates
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
NCT03547115
Recruiting
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
Register for Updates
Determining How Indoor Lighting Affects the Brain Health of Older Adults
NCT05978934
Recruiting
The goal of this randomized, cross-over, single-site trial followed by an exploratory third intervention is to understand how indoor lighting affects different measures of brain health in older adults living in independent living residences. This is a community based study occurring in a local senior living facility. The main question this study aims to answer is: - How does the quality of ambient indoor lighting an older adult is exposed to affect measures of brain health, such as sleep qualit... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/28/2023
Locations: The Waters on Mayowood, Rochester, Minnesota
Conditions: Sleep, Physical Activity, Cognitive Function, Social Isolation
Register for Updates
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
NCT05338073
Recruiting
This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cancer, Predictive Cancer Model, Effects of Chemotherapy
Register for Updates
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
NCT01696721
Recruiting
In previous studies, Proton Beam Radiation Therapy (PBRT) has been found to show better results in treating patients with cancer, both because there is better control of where in the body the radiation is directed and because it is associated with less severe long term side effects. However, there is limited published data demonstrating these results. The goal of the Proton and Photon Consortium Registry (PPCR) is to enroll children treated with radiation in order to describe the population that... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
01/05/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pediatric Patients Treated With Radiation Therapy
Register for Updates
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
NCT05605951
Recruiting
The goal of this observational study is to longitudinally investigating subjects with inaugural acute optic neuritis (ON). The main questions it aims to answer are: * Does the time to corticosteroid treatment affect the visual outcome at 6 months in subjects with acute multiple sclerosis (MS)-, aquaporin 4-IgG positive (AQP4-IgG+) and myelin-oligodendrocyte-glycoprotein-IgG positive (MOG-IgG+) ON? * How differ clinical, structural, and laboratory biomarkers in subjects with acute ON, including... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2022
Locations: Departments of Neurology and Ophthalmology, Mayo Clinic, Rochester, Minnesota
Conditions: Demyelinating Diseases, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Optic Neuritis
Register for Updates
Minnesota RETAIN Impact Evaluation
NCT05146349
Recruiting
This study is a randomized control trial (RCT) to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. Collaboration between partners to implement best practices in early intervention to support injured or ill employees in stay at work and return to work will be implemented.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2022
Locations: Mn Retain, Mayo Clinic, Rochester, Minnesota
Conditions: Any Injury or Illness Acutely Impacting Work
Register for Updates